Follow The Filings

Merck & Co., Inc.

Rahway, NJ 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

  • $526M
  • 13 holdings
  • 2026 Q2
  • +50.7% QoQ
  • Top 5 93.3%

In 2026 Q2 Merck & Co. sold out of Carisma Therapeutics.

Portfolio

2026 Q2, filed 8/7/2026, top 12 of 13 holdings

Top 5 93.3%, top 10 99.8%

  1. PSNL, Personalis 35.8%
  2. MRNA, Moderna 30.7%
  3. KYMR, Kymera Therapeutics 16.8%
  4. AKTS, Aktis Oncology 5.9%
  5. EIKN, Eikon Therapeutics 4.1%
  6. TRDA, Entrada Therapeutics 2.4%
  7. STRO, Sutro Biopharma 1.7%
  8. ALEC, Alector 1.4%
  9. Evaxion Biotech A/s 0.7%
  10. Viridian Therapeutics 0.3%
  11. Xilio Therapeutics 0.2%
  12. Tuhura Biosciences 0.0%
  13. Other 0.0%

AUM over time

2026 Q2 $526M +50.7% QoQ
2025 Q3: $228M 2025 Q3: $228M
Q3 2025
2025 Q4: $276M, +21.1% QoQ 2025 Q4: $276M, +21.1% QoQ
Q4
2026 Q1: $349M, +26.4% QoQ 2026 Q1: $349M, +26.4% QoQ
Q1 2026
2026 Q2: $526M, +50.7% QoQ 2026 Q2: $526M, +50.7% QoQ
Q2

Latest book

2026 Q2 2026 Q1, filed 7 Aug, long equity only

Download CSV Download Excel All activity
PSNL, Personalis 35.75% Hold 14,044,943 $13.40 $188M — —
MRNA, Moderna 30.71% Hold 2,308,190 $70.03 $162M — —
KYMR, Kymera Therapeutics 16.82% Hold 772,165 $114.67 $89M — —
AKTS, Aktis Oncology 5.83% Hold 952,844 $32.23 $31M — —
EIKN, Eikon Therapeutics 4.13% Hold 1,666,666 $13.05 $22M — —
TRDA, Entrada Therapeutics 2.43% New 1,739,768 $7.36 $13M +1,739,768 +$13M
STRO, Sutro Biopharma 1.72% New 272,351 $33.20 $9M +272,351 +$9M
ALEC, Alector 1.35% Hold 3,545,719 $2.01 $7.1M — —
Evaxion Biotech A/s 0.71% New 1,214,126 $3.10 $3.8M +1,214,126 +$3.8M
Viridian Therapeutics 0.33% Hold 93,414 $18.37 $1.7M — —
Xilio Therapeutics 0.19% Hold 105,982 $9.58 $1M — —
Tuhura Biosciences 0.01% Hold 19,445 $2.34 $46K — —
Neuphoria Therapeutics 0.01% Hold 10,027 $4.37 $44K — —

Exits / last held

Gone since 2026 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
TRDA, Entrada Therapeutics 6.28% Exit 0 $12.62 $22M −1,739,768 −$22M
Sutro Biopharma 1.94% Exit 0 $24.91 $6.8M −272,351 −$6.8M
Evaxion Biotech A/s 1.29% Exit 0 $3.72 $4.5M −1,214,126 −$4.5M
Carisma Therapeutics 0.01% Exit 0 $0.0326 $48K −1,473,240 −$48K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2026 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

4 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 13 $526M +50.7% 13F-HR 8/7/2026 000031015826000210
2026 Q1 14 $349M +26.4% 13F-HR 5/13/2026 000031015826000141
2025 Q4 12 $276M +21.1% 13F-HR 2/17/2026 000031015826000055
2025 Q3 13 $228M — 13F-HR 11/12/2025 000031015825000063

About

Merck & Co., Inc.

4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

SEC filing name
Merck & Co., Inc.
Location
Rahway, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf